==Life Span Studies of Atomic Bomb Survivors==

[[File:HHPS Figure 4-4.jpg|thumb|right|Figure 1. From Preston et al. <ref name="2003 Preston" />: Solid cancer dose-response function average over gender for attained age 70 after exposure at age 30. The solid straight-line is the linear slope estimate; the points are dose-category-specific ERR estimates; the dashed curve is a smoothed estimate that is derived from the points; and the dotted curves indicate upper and lower one-stand-error bounds on the smoothed estimate.]]
Survivors of the atomic bomb explosions at Hiroshima and Nagasaki, Japan have been the subjects of a Life Span Study (LSS), which has provided valuable epidemiological data. 

The LSS population went through several changes:</br>
1945   There were some 93,000 individuals, either living in Hiroshima or Nagasaki, Japan;</br>
1950   An additional 37,000 were registered by this time, for a total of 130,000 LSS members.

However, some 44,000 individuals were censured or excluded from the LSS project, so there remained about 86,000 people who were followed through the study.  There is a gap in knowledge of the earliest cancer that developed in the first few years after the war, which impacts the assessment of leukemia to an important extent and for solid cancers to a minor extent.  Table 1 shows summary statistics of the number of persons and deaths for different dose groups. These comparisons show that the doses that were received by the LSS population overlap strongly with the doses that are of concern to NASA Exploration mission (i.e., 50 to 2,000 mSv).
              

{| class="wikitable"  <div style="text-align: center;">
|+''Table 1.  Number of persons, Cancer Deaths, and Non-cancer Deaths for Different Dose Groups in the Life Span Study <ref name=BEIR>{{cite book|last=BEIR|title=Health risks from exposure to low levels of ionizing radiation BEIR VII, Phase 2|year=2006|publisher=National Academies Press|location=Washington, D.C.|isbn=0-309-53040-7|url=http://www.nap.edu/openbook.php?record_id=11340&page=R1|author=Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation|edition=[Online-Ausg.]|coauthors=National Research Council of the National Academies|accessdate=5 July 2012}}</ref>''
!
!colspan="8"|DS86 Weighted Colon Dose, mSv
|-
!
!scope="col" width="75"|Total
!scope="col" width="75"|0-50
!scope="col" width="75"|50-100
!scope="col" width="75"|100-200
!scope="col" width="75"|200-500
!scope="col" width="75"|500-1,000
!scope="col" width="75"|1,000-2,000
!scope="col" width="75"|>2,000
|-
|No. Subjects
| align="center" | 86,572
| align="center" | 37,458
| align="center" | 31,650
| align="center" | 5,732
| align="center" | 6,332
| align="center" | 3,299
| align="center" | 1,613
| align="center" | 488
|-
|Cancer Deaths
| align="center" | 9,335
| align="center" | 3,833
| align="center" | 3,277
| align="center" | 668
| align="center" | 763
| align="center" | 438
| align="center" | 274
| align="center" | 82
|-
|Non-cancer Deaths
| align="center" | 31,881
| align="center" | 13,832
| align="center" | 11,633
| align="center" | 2,163
| align="center" | 2,423
| align="center" | 1,161
| align="center" | 506
| align="center" | 163
|-
|}

Figure 1 shows the dose response for the excess relative risk (ERR) for all solid cancers from Preston et al.<ref name="2003 Preston">{{cite journal|last=Preston|first=DL|coauthors=Shimizu, Y; Pierce, DA; Suyama, A; Mabuchi, K|title=Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997.|journal=Radiation research|year=2003|month=October|volume=160|issue=4|pages=381–407|pmid=12968934|url=http://www.cerrie.org/committee_papers/INFO_12-J.pdf|accessdate=5 July 2012}}</ref>  Tables 2 and 3 show several summary parameters for tissue-specific cancer mortality risks for females and males, respectively, including estimates of ERR, excess absolute risk (EAR), and percentage attributable risks.  Cancer incidence risks from low-LET radiation are about 60% higher than cancer mortality risks. <ref>{{cite journal|last=Preston|first=DL|coauthors=Ron, E; Tokuoka, S; Funamoto, S; Nishi, N; Soda, M; Mabuchi, K; Kodama, K|title=Solid cancer incidence in atomic bomb survivors: 1958-1998.|journal=Radiation research|year=2007|month=July|volume=168|issue=1|pages=1–64|pmid=17722996|accessdate=5 July 2012}}</ref>


{| class="wikitable" <div style="text-align: center;">
|+''Table 2. From Preston et al. <ref name="2003 Preston" />: Tissue-specific Cancer Mortality Risk Summary Statistics 9i.e., ERR, EAR, and Attributable Risks) for Females and Males, Respectively''
|+LSS Female Site-specific Summary Mortality Rate Estimates: Solid Cancers 1950-1997
!scope="col" width="200"|Site/System
!scope="col" width="200"|Deaths</br>(>0.005Sv)
!scope="col" width="200"|ERR/Sv<sup>a</sup></br>(90% CI)
!scope="col" width="200"|EAR/10<sup>4</sup>PY<sup>b</sup> -Sv<sup>c</sup></br>(90%CI)
!scope="col" width="200"|Attributable</br>risk (%)<sup>d</sup>
|-
|''All solid cancer''
| align="center" | 4,884 (2,948)
| align="center" | 0.63 (0.49; 0.79)
| align="center" | 13.5 (7.4; 16.3)
| align="center" | 9.2 (7.4; 11.0)
|-
|''Oral cavity''
| align="center" | 42 (25)
| align="center" | -0.20 (<-0.3; 0.75)
| align="center" | -0.04 (<-0.3; 0.14)
| align="center" | -4.1 (<-6; 14)
|-
|''Digestive System''
|
|
|
|
|-
| align="center" | Esophagus
| align="center" | 67 (44)
| align="center" | 1.7 (0.46; 3.8)
| align="center" | 0.51 (0.15; 0.92)
| align="center" | 22 (6.6; 42)
|-
| align="center" | Stomach
| align="center" | 1,312 (786)
| align="center" | 0.65 (0.40; 0.95)
| align="center" | 3.3 (2.1; 4.7)
| align="center" | 8.8 (5.5; 12)
|-
| align="center" | Colon
| align="center" | 272 (786)
| align="center" | 0.49 (0.11; 1.1)
| align="center" | 0.68 (0.76; 1.3)
| align="center" | 9.0 (4.3; 17)
|-
| align="center" | Rectum
| align="center" | 198 (127)
| align="center" | 0.75 (0.16; 1.6)
| align="center" | 0.69 (0.16; 1.3)
| align="center" | 11.3 (2.6; 22)
|-
| align="center" | Liver
| align="center" | 514 (291)
| align="center" | 0.35 (0.07; 0.72)
| align="center" | 0.85 (0.18; 1.6)
| align="center" | 6.2 (1.3; 12)
|-
| align="center" | Gallbladder
| align="center" | 236 (149)
| align="center" | 0.16 (-0.17; 0.67)
| align="center" | 0.18 (-0.21; 0.71)
| align="center" | 2.6 (-2.9; 10)
|-
| align="center" | Pancreas
| align="center" | 244 (135)
| align="center" | -0.01 (-0.28; 0.45)
| align="center" | -0.01 (-0.35; 0.52)
| align="center" | -0.2 (-5.0; 7.6)
|-
|''Respiratory System''
|
|
|
|
|-
| align="center" | Lung
| align="center" | 548 (348)
| align="center" | 1.1 (0.678; 1.6)
| align="center" | 2.5 (1.6; 3.5)
| align="center" | 16 (10; 22)
|-
| align="center" | Female breast
| align="center" | 272; (173)
| align="center" | 0.79 (0.29; 1.5)
| align="center" | 1.6 (1.2; 2.2)
| align="center" | 24 (18; 32)
|-
| align="center" | Uterus
| align="center" | 518 (323)
| align="center" | 0.17 (-0.10; 0.52)
| align="center" | 0.44 (-0.27; 1.3)
| align="center" | 2.7 (-1.6; 7.9)
|-
| align="center" | Ovary
| align="center" | 136 (85)
| align="center" | 0.94 (0.07; 2.0)
| align="center" | 0.63 (0.23; 1.2)
| align="center" | 15 (5.3; 28)
|-
|''Urinary System''
|
|
|
|
|-
| align="center" | Bladder
| align="center" | 67 (43)
| align="center" | 1.2 (0.10; 3.1)
| align="center" | 0.33 (0.02; 0.74)
| align="center" | 16 (0.9; 36)
|-
| align="center" | Kidney
| align="center" | 31 (21)
| align="center" | 0.97 (<-0.3; 3.8)
| align="center" | 0.14 (<-0.1; 0.42)
| align="center" | 14 (<-3; 42)
|-
|''Brain/CNS<sup>d</sup>''
| align="center" | 17 (10)
| align="center" | 0.51 (<-0.3; 3.9)
| align="center" | 0.04 (<-0.02; 0.2)
| align="center" | 11 (<0.05; 57)
|-
| colspan="5"|<small><sup>a</sup>ERR/SV for age at exposure 30 in an age-constant linear ERR model; <sup>b</sup>Excess absolute risk per 10,000 persons per year; <sup>c</sup>Average EAR computed from ERR model; <sup>d</sup>Attributable risk among survivors whose estimated dose is at least 0.005 Sv; CNS - central nervous system.</small>
|-
|}

{| class="wikitable" <div style="text-align: center;">
|+''Table 3. From Preston et al. <ref name="2003 Preston" />: Tissue-specific Cancer Mortality Risk Summary Statistics 9i.e., ERR, EAR, and Attributable Risks) for Males"
|+LSS Male Site-specific Summary Mortality Rate Estimates: Solid Cancers 1950-1997
!scope="col" width="200"|Site/System
!scope="col" width="200"|Deaths</br>(>0.005Sv)
!scope="col" width="200"|ERR/Sv<sup>a</sup></br>(90% CI)
!scope="col" width="200"|EAR/10<sup>4</sup>PY<sup>b</sup> -Sv<sup>c</sup></br>(90%CI)
!scope="col" width="200"|Attributable</br>risk (%)<sup>d</sup>
|-
|''All solid cancer''
| align="center" | 4,451 (2,554)
| align="center" | 0.37 (0.26; 0.49)
| align="center" | .6 (9.4; 16.2)
| align="center" | 6.6 (4.9; 8.4)
|-
|''Oral cavity''
| align="center" | 68 (37)
| align="center" | -0.20 (<-0.3; 0.45)
| align="center" | -0.12 (<-0.3; 0.25)
| align="center" | -5.2 (<-6; 11)
|-
|''Digestive System''
|
|
|
|
|-
| align="center" | Esophagus
| align="center" | 224 (130)
| align="center" | 0.61 (0.15; 1.2)
| align="center" | 1.1 (0.28; 2.0)
| align="center" | 11.1 (2.8; 21)
|-
| align="center" | Stomach
| align="center" | 1,555 (899)
| align="center" | 0.20 (0.04; 0.39)
| align="center" | 2.1 (0.43; 4.0)
| align="center" | 3.2 (0.07; 6.2)
|-
| align="center" | Colon
| align="center" | 206 (122)
| align="center" | 0.54 (0.13; 1.2)
| align="center" | 1.1 (0.64; 1.9)
| align="center" | 12 (6.9; 21)
|-
| align="center" | Rectum
| align="center" | 172 (96)
| align="center" | -0.25 (<-0.3; 0.15)
| align="center" | -0.41 (<-0.4; 0.22)
| align="center" | -5.4 (<-6; 3.1)
|-
| align="center" | Liver
| align="center" | 722 (408)
| align="center" | 0.59 (0.11; 0.68)
| align="center" | 2.4 (1.2; 4.0)
| align="center" | 8.4 (4.2; 14)
|-
| align="center" | Gallbladder
| align="center" | 92 (52)
| align="center" | 0.89 (0.22; 1.9)
| align="center" | 0.63 (0.17; 1.2)
| align="center" | 17 (4.5; 33)
|-
| align="center" | Pancreas
| align="center" | 163 (103)
| align="center" | -0.11 (<-0.3; 0.44)
| align="center" | -0.15 (<-0.4; 0.58)
| align="center" | --1.9 (<-6; 7.5)
|-
|''Respiratory System''
|
|
|
|
|-
| align="center" | Lung
| align="center" | 716 (406)
| align="center" | 0.48 (0.23; 0.78)
| align="center" | 2.7 (1.4; 4.1)
| align="center" | 9.7 (4.9; 15)
|-
|''Urinary System''
|
|
|
|
|-
| align="center" | Bladder
| align="center" | 82 (56)
| align="center" | 1.1 (0.2; 2.5)
| align="center" | 0.7 (0.1; 1.4)
| align="center" | 17 (3.3; 34)
|-
| align="center" | Kidney
| align="center" | 36 (18)
| align="center" | -0.02 (<-0.3; 1.1)
| align="center" | -0.01 (-0.1; 0.28)
| align="center" | -0.4 (<-5; 22)
|-
|''Brain/CNS<sup>d</sup>''
| align="center" | 14 (9)
| align="center" | 5.3 (1.4; 16)
| align="center" | 0.35 (0.13; 0.59)
| align="center" | 62 (23; 100)
|-
| colspan="5"|<small><sup>a</sup>ERR/SV for age at exposure 30 in an age-constant linear ERR model; <sup>b</sup>Excess absolute risk per 10,000 persons per year; <sup>c</sup>Average EAR computed from ERR model; <sup>d</sup>Attributable risk among survivors whose estimated dose is at least 0.005 Sv; CNS - central nervous system.<\small>
|-
|}

==Other Human Studies==
The BEIR VII Report <ref name=BEIR /> contains an extensive review of data sets from human populations, including nuclear reactor workers and patients who were treated with radiation.  The recent report from Cardis et al.<ref>{{cite journal|last=Cardis|first=E|coauthors=Vrijheid, M; Blettner, M; Gilbert, E; Hakama, M; Hill, C; Howe, G; Kaldor, J; Muirhead, CR; Schubauer-Berigan, M; Yoshimura, T; Bermann, F; Cowper, G; Fix, J; Hacker, C; Heinmiller, B; Marshall, M; Thierry-Chef, I; Utterback, D; Ahn, YO; Amoros, E; Ashmore, P; Auvinen, A; Bae, JM; Bernar, J; Biau, A; Combalot, E; Deboodt, P; Diez Sacristan, A; Eklöf, M; Engels, H; Engholm, G; Gulis, G; Habib, RR; Holan, K; Hyvonen, H; Kerekes, A; Kurtinaitis, J; Malker, H; Martuzzi, M; Mastauskas, A; Monnet, A; Moser, M; Pearce, MS; Richardson, DB; Rodriguez-Artalejo, F; Rogel, A; Tardy, H; Telle-Lamberton, M; Turai, I; Usel, M; Veress, K|title=The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: estimates of radiation-related cancer risks.|journal=Radiation research|year=2007|month=April|volume=167|issue=4|pages=396–416|doi=10.1667/RR0553.1|pmid=17388693|url=http://www.bioone.org/doi/abs/10.1667/RR0553.1|accessdate=5 July 2012}}</ref> describes a meta-analysis for reactor workers from several countries.  A meta-analysis at specific cancer sites, including breast, lung, and leukemia, has also been performed. <ref name=BEIR />  These studies require adjustments for photon energy, dose-rate, and country of origin as well as adjustments made in single population studies.  Table 4 shows the results that are derived from Preston et al. <ref name="2002 Preston">{{cite journal|last=Preston|first=DL|coauthors=Mattsson, A; Holmberg, E; Shore, R; Hildreth, NG; Boice JD, Jr|title=Radiation effects on breast cancer risk: a pooled analysis of eight cohorts.|journal=Radiation research|year=2002|month=August|volume=158|issue=2|pages=220–35|pmid=12105993|url=http://www.jstor.org/stable/10.2307/3580776|accessdate=5 July 2012}}</ref> for a meta-analysis of breast cancer risks in eight populations, including the atomic-bomb survivors.  The median ERR varies by slightly more than a factor of two, but confidence levels significantly overlap.  Adjustments for photon energy or dose-rate and fractionation have not been made.  These types of analysis lend confidence to risk assessments as well as show the limitations of such data sets.

Of special interest to NASA is the age at exposure dependence of low-LET cancer risk projections.  The BEIR VII report <ref name=BEIR /> prefers models that show less than a 25% reduction in risk over the range from 35 to 55 years, while NCRP Report No. 132 <ref>{{cite book|last=NCRP|title=NPRC Report No. 132: Recommendations of dose limits for low Earth orbit|year=2000|publisher=NCRP|location=Bethesda, MD|url=http://www.ncrponline.org/Publications/Press_Releases/132press.html}}</ref> shows about a two-fold reduction over this range.

{| class="wikitable" <div style="text-align: center;"> border="1"
|+''Table 4.  Results from Meta-analysis of Breast Cancer from Eight Population Groups, Including the Life Span Study of Atomic Bomb Survivors and Several Medical Patient Groups Exposed to X Rays, as described in Preston et al. <ref name="2002 Preston" />''
|+Summary of Parameter Estimates for the Final Pooled ERR Model
!scope="col" width="200"|Cohort
!scope="col" width="200"|Reference age for</br>the ERR/Gy estimate
!scope="col" width="200"|ERR/Gy<sup>a</sup>
!scope="col" width="200"|Percentage change</br>per decade increase</br>in age at exposure
!scope="col" width="200"|Exponent of</br>attained age
!scope="col" width="200"|Background</br>SIR<sup>b</sup>
|-
| align="center" | LSS
|attained age 50
| align="center" |2.10</br>(1.6; 2.8)
| align="center" |Not included<sup>b</sup>
| align="center" | -2.0</br>(-2.8; -1.1)
| align="center" | 1.01</br>(0.9; 1.1)
|-
| align="center" | TBO
|attained age 50
| align="center" | 0.74</br>(0.4; 1.2)
| align="center" | Not included
| align="center" | -2.0</br>(-2.8; -1.1)
| align="center" | 0.96</br>(0.7; 1.2)
|-
| align="center" | TBX
|attained age 50
| align="center" | 0.74</br>(0.4; 1.2)
| align="center" | Not included
| align="center" | -2.0</br>(-2.8; -1.1)
| align="center" | 0.73</br>(0.6; 0.9)
|-
| align="center" | THY
|attained age 50
| align="center" | 0.74</br>(0.4; 1.2)
| align="center" | Not included
| align="center" | -2.0</br>(-2.8; -1.1)
| align="center" | 1.05</br>(0.7; 1.5)
|-
| align="center" | BBD
|age at exposure 25
| align="center" | 1.9</br>(1.3; 2.8)
| align="center" | -60%</br>(-71%; -44%)
| align="center" | Not included<sup>c</sup>
| align="center" | 0.98</br>(0.8; 1.2)
|-
| align="center" | APM
|all ages
| align="center" | 0.56</br>(0.3; 0.9)
| align="center" | Not included
| align="center" | Not included
| align="center" | 1.45</br>(1.1; 1.8)
|-
| align="center" | HMG
|all ages
| align="center" | 0.34</br>(0.1; 0.7)
| align="center" | Not included
| align="center" | Not included
| align="center" | 1.07</br>(0.8; 1.3)
|-
| align="center" | HMS
|all ages
| align="center" | 0.34</br>(0.1; 0.7)
| align="center" | Not included
| align="center" | Not included
| align="center" | 1.05</br>(0.9; 1.2)
|-
| colspan="6"|<small><sup>a</sup> C.I.'s within parentheses; <sup>b</sup>SIR = standardized incidence ratio; <sup>c</sup>"Not included" means that the risk is assumed not to vary with age at exposure (attained age).</small>
|-
|}

==References==
{{reflist|2}}

{{NASA|article=Human Health and Performance Risks of Space Exploration Missions|url=http://humanresearchroadmap.nasa.gov/evidence/reports/EvidenceBook.pdf|comment=NASA SP-2009-3405, pp. 132-134}}

{{Space medicine}}

[[Category:Health sciences]]
[[Category:Occupational safety and health]]
[[Category:Space medicine]]